Flux Power reported a significant revenue decline to $6.8M for the quarter ended September 30, 2026, compared to $13.2M in the prior year, leading to a net loss of $3.2M. The company highlighted substantial risks including an event of default under its credit facility with Gibraltar Business Capital and concerns regarding its ability to continue as a going concern.
Calix, Inc. reported total revenue of $301.7 million for the third quarter of 2026, a 13.7% increase year-over-year, driven by growth in both appliance and software/service segments. Net income for the nine months ended September 26, 2026, rose significantly to $38.5 million compared to $10.7 million in the prior year, despite a substantial $290.2 million cash outflow for common stock repurchases.
Amgen reported third quarter 2026 financial results with total revenues increasing 8% year-over-year to $10.4 billion, driven by volume growth across its commercial portfolio. GAAP EPS rose 19% to $7.08, while the company generated $3.7 billion in free cash flow during the period.
Term
Q3 2026
“Amgen delivered another strong quarter as our strategy for long-term growth continued to produce results across the enterprise. The strength of our commercial portfolio, combined with important clinical advances and a promising late-stage pipeline, reinforces our confidence in Amgen’s ability to deliver durable growth well into the next decade.”
Robert A. Bradway, chairman and chief executive officer
Angi Inc. reported Q3 2026 financial results with revenue of $242.0 million, a 9% year-over-year decrease, and net earnings of $1.3 million. The company also announced a workforce reduction of approximately 300 roles aimed at generating $50-$60 million in annual run-rate savings to improve organizational velocity and profitability.
Term
Q3 2026
“Angi has one of the most recognized brands in home services, a large network of Pros and an enormous market opportunity. My first 45 days have reinforced my conviction in the potential of this business. We're building on the work already underway to simplify how we operate, move faster and develop better products using technology and AI. I see significant opportunities to improve profitability and cash flow in the near term while building a stronger company positioned for long-term growth.”
SSR Mining reported Q3 2026 net income of $94.8 million and adjusted net income of $130.7 million, driven by production of 103,585 gold equivalent ounces. The company maintained its full-year production guidance but noted that AISC is expected to trend 10% above the original guidance range due to inflation and mine resequencing. SSR Mining also declared a quarterly dividend of $0.03 per share and highlighted its strategic repositioning to an Americas-focused producer following the sale of its Hod Maden stake.
For the nine months ended September 30, 2026, Stoke Therapeutics reported a net loss of $185.3 million, a significant reversal from a net income of $51.0 million in the prior year period, primarily due to a sharp decrease in revenue from $183.0 million to $26.8 million. Operating expenses rose substantially, with research and development costs increasing by 55% to $149.0 million as the company advances its clinical programs for zorevunersen.
For the nine months ended September 30, 2026, SLR Private Credit BDC II LLC reported total investment income of $3.79 million and net investment income of $1.49 million. The company's net asset value per unit increased to $16.37 from $16.01 at the end of 2025, while total unitholders' capital grew to $19.54 million despite $0.8 million in distributions.
For the nine months ended September 30, 2026, Ardelyx reported total revenues of $343.0 million, a significant increase from $282.1 million in the prior year period, driven primarily by net product sales of IBSRELA and XPHOZAH. Despite the revenue growth, the company recorded a net loss of $55.1 million for the first nine months of 2026, though this was an improvement over the $61.2 million net loss in the same period of 2025.
SCP Private Credit Income BDC LLC reported a net increase in unitholders' capital resulting from operations of $2.6 million for the nine months ended September 30, 2026, down from $7.0 million in the prior year period. The company's net asset value per unit decreased to $9.01 from $9.42 at the end of 2025, primarily driven by net unrealized losses on investments and distributions to unitholders.
For the nine months ended September 30, 2026, SLR HC BDC LLC reported total investment income of $7.1 million and net investment income of $3.1 million. The company's net asset value per unit decreased slightly to $20.87 from $21.11 at the end of 2025, while total unitholders' capital grew to $60.7 million due to $16.7 million in capital contributions.
RxSight reported Q3 2026 revenue of $24.6 million, a 19% decrease year-over-year, primarily due to competitive pressures. The company highlighted a strengthened commercial leadership team and a $60 million cash infusion from its strategic collaboration with Alcon, ending the quarter with $254.7 million in cash and investments.
Term
3 months
“Since I joined last quarter, the team has moved quickly and accomplished a great deal in a short period of time. We have strengthened our commercial organization and leadership, made progress across key long-term growth initiatives, and taken decisive actions to align our cost structure with our priorities. While there is more work ahead, we remain focused on execution. Based on our progress, I am confident we are positioning our company for long-term success.”
Aziz Mottiwala, President and Chief Executive Officer
Sixth Street Specialty Lending reported third quarter 2026 financial results with net investment income of $0.44 per share and a net asset value of $16.19 per share. The company also declared a fourth quarter base dividend of $0.42 per share and a third quarter supplemental dividend of $0.01 per share.
“Our objective is not to compete for the same investments on the same terms, but to bring a differentiated perspective to where and how we invest capital. We believe these capabilities position us well to navigate an increasingly bifurcated market and compound long-term value for our shareholders.”
Skyworks Solutions reported Q4 fiscal 2026 standalone revenue of $1.046 billion and non-GAAP diluted EPS of $1.28. The company highlighted the completion of its combination with Qorvo, which closed after the quarter end, creating a full-stack RF front-end platform targeting $500 million in annual cost synergies. For the full fiscal year 2026, Skyworks reported revenue of $3.96 billion.
“Combining with Qorvo gives us the scale and the technology breadth to lead the next era of wireless, as AI moves from the infrastructure to the devices, vehicles and machines around us.”
Phil Brace, chief executive officer and president of Skyworks
“Because our combination with Qorvo closed after the end of our fiscal fourth quarter, our reported September-quarter results are Skyworks standalone.”
Philip Carter, chief financial officer and senior vice president of Skyworks
Arvinas, Inc. reported total assets of $607.5 million as of September 30, 2026, a decrease from $717.9 million at the end of 2025, primarily driven by a reduction in marketable securities and the recognition of deferred revenue. The company maintains a cash runway expected to fund operations into the second half of 2028, focusing on clinical advancements for candidates like ARV-393 and ARV-027.
Vertex Pharmaceuticals reported total revenues of $3.44 billion for the third quarter of 2026, a 12% increase compared to the same period in 2025. Net income for the quarter was $653.6 million, down from $1.08 billion in the prior year, primarily driven by significantly higher operating expenses and a $9.06 billion acquisition of Crinetics Pharmaceuticals.
Sotera Health reported a significant increase in net income for the nine months ended September 30, 2026, reaching $138.6 million compared to $43.1 million in the prior year period. This growth was driven by higher service revenues and the absence of the $64.9 million Illinois EO litigation settlement charge that impacted 2025 results.
Transcat Inc. reported total revenue of $97.1 million for the second quarter ended September 26, 2026, an 18% increase year-over-year, driven primarily by strong growth in Service revenue. Despite the revenue growth, net income for the six-month period decreased to $3.7 million from $4.5 million in the prior year, impacted by higher operating expenses and interest costs.
Booking Holdings reported Q3 2026 financial results featuring 10% gross bookings growth and a 17% increase in adjusted EPS despite a 1% decline in GAAP revenue. The company recorded a $900 million revenue reduction related to an FTC matter and returned capital to shareholders through $2.1 billion in stock repurchases and a quarterly dividend declaration.
Term
Q3 2026
“We are pleased with our third-quarter operating performance, as resilient travel demand and disciplined execution by our teams drove double-digit gross bookings growth, margin expansion, and 17% adjusted earnings per share growth (GAAP earnings per share growth of 7%)”
Glenn Fogel, Chief Executive Officer of Booking Holdings
For the nine months ended September 30, 2026, UnitedHealth Group reported total revenues of $336.4 billion and net earnings attributable to common shareholders of $15.9 billion, an increase from $12.0 billion in the prior year period. The company maintained a strong balance sheet with $312.8 billion in total assets and returned $11.3 billion to shareholders through dividends and share repurchases during the first nine months of 2026.
Ardelyx reported Q3 2026 total product revenue of $125.5 million, a 19% increase year-over-year, driven primarily by $96.3 million in IBSRELA sales. The company reiterated its full-year 2026 revenue guidance for IBSRELA ($350M-$370M) and XPHOZAH ($110M-$120M) while maintaining a strong cash position of $285.3 million.
Term
Q3 2026
“Our third quarter results reflect the strength of the foundation we’ve built. IBSRELA year-over-year growth of 23% is the engine driving total product revenue of over $125 million for the quarter. With our robust tenapanor intellectual property portfolio, and our fully enrolled Phase 3 ACCEL trial for CIC, the value of IBSRELA continues to strengthen. Finally, with over $285 million in cash and investments, and a disciplined capital allocation strategy, we are well positioned to create and deliver significant long-term value.”
Mirum Pharmaceuticals reported Q3 2026 net product sales of $185.7 million, driven by strong performance from LIVMARLI and Bile Acid Medicines. The company increased its full-year 2026 net product sales guidance to a range of $715 million to $720 million following the FDA approval and launch of ATEBRIOZ for FOP.
“The third quarter was an important period of execution for Mirum, with the approval and launch of ATEBRIOZ and positive Phase 3 results across our late-stage rare liver portfolio. Positive results from AZURE-1 and additional data we’ll be sharing at AASLD reinforce the potential of brelovitug to become an important new treatment for chronic HDV, while EXPAND results support the potential to bring LIVMARLI to more patients living with rare cholestatic liver diseases, including biliary atresia.”
Transcat reported fiscal second quarter 2027 results featuring 18% total revenue growth to $97.1 million and 23% growth in its Service segment. The company achieved its 70th consecutive quarter of Service revenue growth and expanded Service gross margins by 220 basis points to 34%.
Term
Q2 2027
“Our fiscal second quarter results demonstrate strong execution across each pillar of our core strategy: driving strong Service organic revenue growth, expanding Service gross margins, executing strategic acquisitions, and growing Rentals consistently.”
Jaime Irick, President and CEO
“For the full fiscal year 2027, assuming the broader economic environment remains stable, we now expect Service organic revenue growth in the low double digits, up from our prior outlook of high single digits, along with Service gross margin expansion.”
Denali Therapeutics reported Q3 2026 financial results, highlighted by $17.8 million in net product revenue for AVLAYAH and a net income of $70.1 million. The company's cash position reached $1.0 billion, bolstered by a $194.0 million net gain from the sale of a Priority Review Voucher.
Term
Q3 2026
“Families and physicians are telling us that AVLAYAH is making a difference for children with Hunter syndrome, and the results this quarter reflect that. The positive responses to AVLAYAH across patients, physicians and payers, and our team’s strong commercial execution, show what is possible for our TransportVehicle portfolio.”
Ryan Watts, Ph.D., Chief Executive Officer of Denali Therapeutics
Avis Budget Group reported third quarter 2026 revenues of $3.4 billion and net income of $199 million. The company achieved record third-quarter Americas vehicle utilization of 74.1% and announced plans to redeem $350 million of its 5.750% Senior Notes due 2027.
Term
Q3 2026
“The third quarter demonstrated continued progress in how we manage our fleet, with third-quarter Americas utilization being the best we have had in twenty years despite a softer travel demand environment. We are building on the improvements we've made in fleet management and field operations with the objective of improving transaction economics, strengthening profitability, and delivering more consistent financial performance over time.”
Versant Media Group reported net income of $47 million for the third quarter of 2026, a decrease from $79 million in the prior year period, driven by lower revenues and higher interest expenses following its separation from Comcast. The company significantly increased its cash position to $1.05 billion and executed $300 million in share repurchases during the first nine months of the year.
Curaleaf Holdings reported record third-quarter 2026 revenue of $352.7 million, a 10.9% year-over-year increase driven by strong domestic and international growth. Despite the revenue record, the company reported a net loss from continuing operations of $37.4 million for the quarter, while maintaining an adjusted EBITDA margin of 22%.
Term
Q3 2026
“We are building the global leader in cannabis, and our third-quarter results provide further evidence that our strategy is delivering. Solid execution across the business is driving growth, strengthening our competitive position, and advancing our Built for Growth plan.”
Boris Jordan, Chairman and CEO
“These results reflect the disciplined execution of our entire team and reinforce the strength of our global platform. We are translating operational improvements into stronger financial performance, building momentum across the business, and positioning Curaleaf for sustained growth and greater cash generation.”
For the nine months ended September 30, 2026, Sixth Street Specialty Lending reported total investment income of $290.2 million and net investment income of $122.3 million, down from $159.5 million in the prior year period. Net asset value per share decreased to $16.19 from $16.98 at year-end 2025, primarily driven by net realized and unrealized losses totaling $73.4 million.
Gladstone Commercial Corporation reported financial results for the third quarter ended September 30, 2026, including total operating revenue of $42.4 million. The company reported a net loss available to common stockholders of $5.2 million, or $0.11 per share, primarily impacted by a $6.5 million impairment charge. Core FFO for the quarter was $16.9 million, or $0.35 per diluted share.
Manitowoc reported strong third-quarter 2026 results with net sales of $613.8 million, up 10.9% year-over-year, and a 37.6% surge in orders to $676.4 million. Driven by robust crane demand in the Americas and Middle East, the company raised its full-year 2026 adjusted EBITDA and adjusted EPS guidance.
Term
Q3 2026
“Manitowoc’s third quarter results exceeded our expectations, highlighted by robust orders, double-digit sales growth, and a significant improvement in adjusted EBITDA. Backlog expanded over the last four consecutive quarters, reflecting continued strength in crane demand, particularly in the Americas, Middle East, and Asia Pacific, providing good visibility to the fourth quarter and into 2027.”
Aaron H. Ravenscroft, President and Chief Executive Officer
“For the remainder of the year, our priorities remain clear: execute against our backlog, improve working-capital efficiency, and continue to grow the aftermarket business through our CRANES+50 strategy. Given our strong momentum, we have raised our guidance for adjusted EBITDA and adjusted diluted earnings per share.”
Aaron H. Ravenscroft, President and Chief Executive Officer
Spyre Therapeutics reported third quarter 2026 financial results, highlighting a pro forma cash position of $1.5 billion following a $400 million public offering in October. The company achieved clinical proof-of-concept for its three IBD monotherapies and is advancing combination trials with data expected in Q3 2027.
Term
Q3 2026
“We are increasingly well-positioned to deliver on our ambition of elevating the standard of care across immunology. In IBD, our three compelling Phase 2 monotherapy readouts and a growing body of supportive clinical evidence strengthen our conviction that our combination products have the potential to transform the treatment paradigm.”
Cameron Turtle, DPhil, Chief Executive Officer of Spyre